Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19606063rdf:typepubmed:Citationlld:pubmed
pubmed-article:19606063lifeskim:mentionsumls-concept:C0002395lld:lifeskim
pubmed-article:19606063lifeskim:mentionsumls-concept:C0080103lld:lifeskim
pubmed-article:19606063lifeskim:mentionsumls-concept:C0025250lld:lifeskim
pubmed-article:19606063lifeskim:mentionsumls-concept:C0021669lld:lifeskim
pubmed-article:19606063lifeskim:mentionsumls-concept:C0521117lld:lifeskim
pubmed-article:19606063lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:19606063lifeskim:mentionsumls-concept:C1287349lld:lifeskim
pubmed-article:19606063pubmed:issue8lld:pubmed
pubmed-article:19606063pubmed:dateCreated2009-7-31lld:pubmed
pubmed-article:19606063pubmed:abstractTextExperimental reduction of neprilysin (NEP) or insulin-degrading enzyme (IDE) in vivo exacerbates beta-amyloid accumulation in the brain. The level of these enzymes is reportedly reduced during aging and in postmortem brains of patients with sporadic Alzheimer disease (AD). To distinguish between primary decreases in NEP and IDE activity that might contribute to beta-amyloid accumulation and decreases secondary to neurodegenerative changes in AD, we measured NEP and IDE levels by indirect sandwich ELISA and enzyme activities by immunocapture-based fluorogenic assays in postmortem frontal cortex from patients of different ages and at different pathological stages of AD, as indicated by Braak tangle stage. The ELISA measurements of neuron-specific enolase were used to adjust for neuronal loss. Both unadjusted and neuron-specific enolase-adjusted NEP levels and activity were significantly increased in AD and positively correlated with Braak stage but negatively with age in AD patients. Insulin-degrading enzyme activity was higher in AD than controls; this was significant after adjustment for neuron-specific enolase level; unadjusted IDE protein level was decreased in AD but not after adjustment. Our findings suggest that reduction in NEP and IDE activity is not the primary cause of beta-amyloid accumulation in AD, but rather a late-stage phenomenon secondary to neurodegeneration.lld:pubmed
pubmed-article:19606063pubmed:languageenglld:pubmed
pubmed-article:19606063pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19606063pubmed:citationSubsetIMlld:pubmed
pubmed-article:19606063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19606063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19606063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19606063pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19606063pubmed:statusMEDLINElld:pubmed
pubmed-article:19606063pubmed:monthAuglld:pubmed
pubmed-article:19606063pubmed:issn0022-3069lld:pubmed
pubmed-article:19606063pubmed:authorpubmed-author:LoveSethSlld:pubmed
pubmed-article:19606063pubmed:authorpubmed-author:BaigShabnamSlld:pubmed
pubmed-article:19606063pubmed:authorpubmed-author:MinersJames...lld:pubmed
pubmed-article:19606063pubmed:authorpubmed-author:KehoePatrick...lld:pubmed
pubmed-article:19606063pubmed:authorpubmed-author:TaylerHannahHlld:pubmed
pubmed-article:19606063pubmed:issnTypePrintlld:pubmed
pubmed-article:19606063pubmed:volume68lld:pubmed
pubmed-article:19606063pubmed:ownerNLMlld:pubmed
pubmed-article:19606063pubmed:authorsCompleteYlld:pubmed
pubmed-article:19606063pubmed:pagination902-14lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:meshHeadingpubmed-meshheading:19606063...lld:pubmed
pubmed-article:19606063pubmed:year2009lld:pubmed
pubmed-article:19606063pubmed:articleTitleNeprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.lld:pubmed
pubmed-article:19606063pubmed:affiliationDementia Research Group, Clinical Science at North Bristol, University of Bristol, Frenchay Hospital, Frenchay, Bristol, United Kingdom. scott.miners@bristol.ac.uklld:pubmed
pubmed-article:19606063pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19606063pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:4311entrezgene:pubmedpubmed-article:19606063lld:entrezgene
entrez-gene:3416entrezgene:pubmedpubmed-article:19606063lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19606063lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19606063lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19606063lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19606063lld:pubmed